

LITERATURA

1. Burdová K. Přímá perorální antikoagulační. *Klin Farmakol Farm.* 2015; 29(4): 138–143.
2. Zatloukalová A, Janoutová J, Homza M, Janout V. Epidemiologická studie nových perorálních antikoagulancií. *Klin Farmakol Farm.* 2018; 32(2), 3–7.
3. Kvasnička J, Penka M, Kvasnička T, a kol. Doporučení české společnosti pro trombózu a hemostázu České lékařské společnosti J. E. Purkyně pro bezpečnou léčbu novými perorálními antikoagulanty (NOAC) – dabigatran exilátem, apixabanem a rivaroxabanem. *Vnitř. Lék.* 2015; 61(6): 537–546.
4. Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. *New England Journal of Medicine* [online]. 2019 [cit. 2019–03–26]. DOI: 10.1056/NEJMoa1814051. ISSN 0028–4793. Dostupné z: <http://www.nejm.org/doi/10.1056/NEJMoa1814051>
5. Karetová D, Bultas J. Řešení urgentních stavů spojených s rizikem krvácení u nemocných užívajících nová perorální antikoagulační – možnosti ukončení účinku. *Remedia.* 26(2): 235–240.
6. Ramacciotti E, Hoppensteadt D, Fareed J. Betrixaban for VTE Prevention in the Medically Ill Population, the APEX Trial: Good News for This Needy Population? *Clinical and Applied Thrombosis/Hemostasis* [online]. 2016; 23(7), 701–702 [cit. 2019–02–25]. DOI: 10.1177/1076029616683805. ISSN 1076–0296. Dostupné z: <http://journals.sagepub.com/doi/10.1177/1076029616683805>
7. Skelley J, Thomason A, Nolen J. Betrixaban (Bevyxxa): A Direct-Acting Oral Anticoagulant Factor Xa Inhibitor. *P & T: a peer-reviewed journal for formulary management* [online]. 2018; 43(2), 85–120 [cit. 2019–02–25]. Dostupné z: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768296/>
8. Dobesh PP, Trevarrow BJ. Betrixaban: Safely Reducing Venous Thromboembolic Events with Extended Prophylaxis. *The American Journal of Medicine* [online]. 2018; 123(1), 02–25. DOI: 10.1016/j.amjmed.2018.08.024. ISSN 00029343. Dostupné z: <https://linkinghub.elsevier.com/retrieve/pii/S0002934318308520>
9. Lekura J, Kalus JS. Overview of betrixaban and its role in clinical practice. *American Journal of Health-System Pharmacy* [online]. 2018; 75(15), 1095–1102 [cit. 2019–02–25]. DOI: 10.2146/ajhp170785. ISSN 1079–2082. Dostupné z: <https://academic.oup.com/ajhp/article/75/15/1095/5102024>
10. Beyer-Westendorf J, Verhamme P, Bauersachs R. Betrixaban for prevention of venous thromboembolism in acute medically ill patients. *European Heart Journal Supplements* [online]. 2018; 20(suppl E), E16–E22 [cit. 2019–02–25]. DOI: 10.1093/eurheartj/suy017. ISSN 1520–765X. Dostupné z: https://academic.oup.com/eurheartjsupp/article/20/suppl_E/E16/4993363
11. Iwatsuki Y, Sato T, Moritani Y, Shigenaga T, et al. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. *European Journal of Pharmacology* [online]. 2011; 673(1–3), 49–55 [cit. 2019–03–19]. DOI: 10.1016/j.ejphar.2011.10.009. ISSN 00142999. Dostupné z: <https://linkinghub.elsevier.com/retrieve/pii/S0014299911012398>
12. Kaku S, Suzuki M, Saitoh M, Funatsu T, et al. Darexaban: Anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa. *Thrombosis Research* [online]. 2013; 131(5), 450–456 [cit. 2019–03–19]. DOI: 10.1016/j.thromres.2013.03.016. ISSN 00493848. Dostupné z: <https://linkinghub.elsevier.com/retrieve/pii/S0049384813001035>
13. Kadokura T, Kashiwa M, Groenendaal D, Heeringa M, et al. Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects. *Biopharmaceutics & Drug Disposition* [online]. 2013; 34(8), 431–441 [cit. 2019–03–19]. DOI: 10.1002/bdd.1858. ISSN 01422782. Dostupné z: <http://doi.wiley.com/10.1002/bdd.1858>
14. Hashimoto T, Suzuki K, Kihara Y, et al. Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans. *Xenobiotica* [online]. 2012; 43(6), 534–547 [cit. 2019–03–19]. DOI: 10.3109/00498254.2012.738045. ISSN 0049–8254. Dostupné z: <http://www.tandfonline.com/doi/full/10.3109/00498254.2012.738045>
15. Kadokura T, Groenendaal D, Heeringa M, Mol R, et al. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin. *European Journal of Drug Metabolism and Pharmacokinetics* [online]. 2014; 39(1), 1–9 [cit. 2019–03–19]. DOI: 10.1007/s13318–013–0141–1. ISSN 0378–7966. Dostupné z: <http://link.springer.com/10.1007/s13318–013–0141–1>
16. Kadokura T, Taniuchi Y, Inoue H, Saito M, et al. Effect of food on the pharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjects. *Int. Journal of Clinical Pharmacology and Therapeutics* [online]. 2013; 51(03), 200–206 [cit. 2019–03–19]. DOI: 10.5414/CP201804. ISSN 0946–1965. Dostupné z: http://www.dustri.com/article_response_page.html?artId=10188&doi=10.5414/CP201804&L=0
17. Eriksson B I, Turpie AGG, Lassen MR, et al. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). *Journal of Thrombosis and Haemostasis* [online]. 2010; 8(4), 714–721 [cit. 2019–03–20]. DOI: 10.1111/j.1538–7836.2010.03748.x. ISSN 15387933. Dostupné z: <http://doi.wiley.com/10.1111/j.1538–7836.2010.03748.x>
18. Steg PG, Mehta SR, Jukema JW, et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. *European Heart Journal* [online]. 2011; 32(20), 2541–2554 [cit. 2019–03–20]. DOI: 10.1093/eurheartj/ehr334. ISSN 0195–668X. Dostupné z: <https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehr334>
19. Sakon M, Nakamura M. Darexaban (YM150) prevents venous thromboembolism in Japanese patients undergoing major abdominal surgery: Phase III randomized, mechanical prophylaxis-controlled, open-label study. *Thrombosis Research* [online]. 2012; 130(3), e52–e59 [cit. 2019–03–20]. DOI: 10.1016/j.thromres.2012.06.009. ISSN 00493848. Dostupné z: <https://linkinghub.elsevier.com/retrieve/pii/S0049384812002800>
20. Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Rocha E, et al. New parenteral anticoagulants in development. *Therapeutic Advances in Cardiovascular Disease* [online]. 2011; 5(1), 33–59 [cit. 2019–03–25]. DOI: 10.1177/1753944710387808. ISSN 1753–9447. Dostupné z: <http://journals.sagepub.com/doi/10.1177/1753944710387808>
21. Hinder M, Frick A, Jordaan P, Hesse G, et al. Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. *Clinical Pharmacology & Therapeutics* [online]. 2006; 80(6), 691–702 [cit. 2019–03–25]. DOI: 10.1016/j.clpt.2006.09.002. ISSN 00099236. Dostupné z: <http://doi.wiley.com/10.1016/j.clpt.2006.09.002>
22. Cohen M, Bhatt DL, Alexander JH, et al. Randomized, Double-Blind, Dose-Ranging Study of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. *Circulation* [online]. 2007; 115(20), 2642–2651 [cit. 2019–03–25]. DOI: 10.1161/CIRCULATIONAHA.106.653428. ISSN 0009–7322. Dostupné z: <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.106.653428>
23. Sabatine MS, EM Antman, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. *The Lancet* [online]. 2009; 374(9692), 787–795 [cit. 2019–03–25]. DOI: 10.1016/S0140–6736(09)61454–9. ISSN 01406736. Dostupné z: <https://linkinghub.elsevier.com/retrieve/pii/S0140673609614549>
24. Dillinger J-G, Gregory DUCROCQ, Elbez Y, et al. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment–Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors. *Circulation: Cardiovascular Interventions* [online]. 2018; 11(6) [cit. 2019–03–26]. DOI: 10.1161/CIRCINTERVENTIONS.118.006084. ISSN 1941–7640. Dostupné z: <https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.118.006084>
25. Deharo P, Ducrocq G, Bode CH, et al. Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment–Elevation Myocardial Infarction Managed Invasively. *Circulation* [online]. 2017; 136(20), 1895–1907 [cit. 2019–03–26]. DOI: 10.1161/CIRCULATIONAHA.117.029779. ISSN 0009–7322. Dostupné z: <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.029779>
26. Steg PG. Anticoagulation With Otamixaban and Ischemic Events in Non-ST-Segment Elevation Acute Coronary Syndromes. *JAMA* [online]. 2013; 310(11) [cit. 2019–03–26]. DOI: 10.1001/jama.2013.277165. ISSN 0098–7484. Dostupné z: <http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2013.277165>
27. Dhakal P, Rayamajhi S, Verma V, Gundabolu K, Bhatt VR. Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants. *Clinical and Applied Thrombosis/Hemostasis* [online]. 2016; 23(5), 410–415 [cit. 2019–03–27]. DOI: 10.1177/1076029616675970. ISSN 1076–0296. Dostupné z: <http://journals.sagepub.com/doi/10.1177/1076029616675970>
28. Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. *Nature Reviews Cardiology* [online]. 2018; 15(5), 273–281 [cit. 2019–03–27]. DOI: 10.1038/nrcardio.2017.223. ISSN 1759–5002. Dostupné z: <http://www.nature.com/doifinder/10.1038/nrcardio.2017.223>
29. Crowther M, Cuker A. How can we reverse bleeding in patients on direct oral anticoagulants? *Kardiologia Polska* [online]. 2019; 77(1), 3–11 [cit. 2019–03–27]. DOI: 10.5603/KP.a2018.0197. ISSN 1897–4279. Dostupné z: <https://ojs.kardiologiapolska.pl/kp/article/view/12634>
30. Ansell JE, Bakhrin SH, Lauch BE, et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. *Thrombosis and Haemostasis* [online]. 2017; 117(02), 238–245 [cit. 2019–03–27]. DOI: 10.1160/TH16–03–0224. ISSN 0340–6245. Dostupné z: <http://www.thieme-connect.de/DOI/DOI?10.1160/TH16–03–0224>
31. Dabi A, Koutrouvelis AP. Reversal Strategies for Intracranial Hemorrhage Related to Direct Oral Anticoagulant Medications. *Critical Care Research and Practice* [online]. 2018; 2018, 1–11 [cit. 2019–03–27]. DOI: 10.1155/2018/4907164. ISSN 2090–1305. Dostupné z: <https://www.hindawi.com/journals/ccrp/2018/4907164/>
32. Riley TR, Gauthier-Lewis ML, Sanchez CHK, DOUGLAS JS. Role of agents for reversing the effects of target-specific oral anticoagulants. *American Journal of Health-System Pharmacy* [online]. 2017; 74(2), 54–61 [cit. 2019–03–27]. DOI: 10.2146/ajhp150810. ISSN 1079–2082. Dostupné z: <https://academic.oup.com/ajhp/article/74/2/54/5102888>